The knockdown of miRNA20a sensitized CRC cell lines to cisplatin therapy through activation of ROS/ASK1/JNK pathway44, recommending its service as a follow-up response marker by Xiao et al.45. The gene discussed is MAP3K5; the disease is colorectal carcinoma.